ALGN vs. EXAS: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ALGN and EXAS, comparing key factors like performance, valuation metrics, dividends, and financial strength.
Company Overview
ALGN’s market capitalization stands at 13.54 billion USD, while EXAS’s is 10.50 billion USD, indicating their market valuations are broadly comparable.
ALGN’s beta of 1.64 points to significantly higher volatility compared to EXAS (beta: 0.98), suggesting ALGN has greater potential for both gains and losses relative to market movements.
| Symbol | ALGN | EXAS |
|---|---|---|
| Company Name | Align Technology, Inc. | Exact Sciences Corporation |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Medical - Devices | Medical - Diagnostics & Research |
| CEO | Mr. Joseph M. Hogan | Mr. Kevin T. Conroy J.D. |
| Price | 186.83 USD | 55.66 USD |
| Market Cap | 13.54 billion USD | 10.50 billion USD |
| Beta | 1.64 | 0.98 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | January 30, 2001 | February 1, 2001 |
| ADR | No | No |
Performance Comparison
This chart compares the performance of ALGN and EXAS over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
This section compares the market valuation of ALGN and EXAS. Key takeaways regarding their valuation, when viewed within their industry context, are presented in the commentary that follows.
- EXAS’s Price-to-Earnings (P/E) ratio of -10.20 is negative. This indicates the company is currently not generating profit, a key factor that can weigh on its stock valuation and investor sentiment.
- ALGN’s Forward PEG ratio of 3.17 is very high, suggesting its stock might be overvalued if its price has substantially outrun its future earnings growth forecast. EXAS’s Forward PEG ratio of -9.46 is negative, often an indicator of issues such as negative current earnings or anticipated earnings contraction, which calls its fundamental valuation into question.
| Symbol | ALGN | EXAS |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 33.56 | -10.20 |
| Forward PEG Ratio (TTM) | 3.17 | -9.46 |
| Price-to-Sales Ratio (P/S, TTM) | 3.40 | 3.71 |
| Price-to-Book Ratio (P/B, TTM) | 3.62 | 4.34 |
| EV-to-EBITDA (TTM) | 15.90 | -14.93 |
| EV-to-Sales (TTM) | 3.21 | 4.48 |
Dividend Comparison
Neither ALGN nor EXAS currently pays a dividend; this often suggests they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
| Symbol | ALGN | EXAS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
Explore the financial strength details for ALGN and EXAS in the table below.
| Symbol | ALGN | EXAS |
|---|---|---|
| Current Ratio (TTM) | 1.21 | 2.73 |
| Quick Ratio (TTM) | 1.08 | 2.38 |
| Debt-to-Equity Ratio (TTM) | 0.03 | 1.05 |
| Debt-to-Asset Ratio (TTM) | 0.02 | 0.44 |
| Net Debt-to-EBITDA Ratio (TTM) | -0.94 | -2.56 |
| Interest Coverage Ratio (TTM) | -- | -57.46 |